This article is more than 5 years old. Information may no longer be current.

Adaptimmune executive: T-cell therapy induces response in synovial sarcoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Rafael Amado, MD, president of research and development for Adaptimmune, spoke with HemOnc Today at ASCO Annual Meeting about the company’s efforts to use T-cell therapy to treat cancer.

Amado highlighted the company’s efforts to use the T-cell therapy ADP-A2M4 to target MAGE-A4, an antigen expressed in a number of solid tumors.

The company has used this therapeutic approach to treat 10 patients with synovial sarcoma. Five have achieved responses. Three others have had dramatic tumor shrinkage and may show partial response on subsequent CT scans, Amado said.

“These are patients who have exhausted all therapies, so this is quite important for the sarcoma field,” Amado told HemOnc Today.

Researchers have observed sporadic evidence of activity in patients with other malignancies, Amado said.

He also highlighted progress in other malignancies, as well as its plan to expand its clinical trials program. – by Mark Leiser